<- Go Home
Harrow, Inc.
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
Market Cap
EUR 1.6B
Volume
526.8K
Cash and Equivalents
EUR 72.6M
EBITDA
EUR 2.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 122.7M
Profit Margin
72.56%
52 Week High
EUR 59.23
52 Week Low
EUR 8.72
Dividend
N/A
Price / Book Value
26.95
Price / Earnings
-46.69
Price / Tangible Book Value
-11.71
Enterprise Value
EUR 1.7B
Enterprise Value / EBITDA
400.77
Operating Income
-EUR 8.6M
Return on Equity
-50.23%
Return on Assets
-1.68
Cash and Short Term Investments
EUR 74.1M
Debt
EUR 196.1M
Equity
EUR 57.6M
Revenue
EUR 169.1M
Unlevered FCF
EUR 62.6M
Sector
Pharmaceuticals
Category
N/A